ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine
WESTON, Fla.–(BUSINESS WIRE)–ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing. These funds will enable the company to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization … [Read more…]
